Friday 6-20-2014 Merck & Company (MRK) $MRK opened at 58.61 hitting the high price of 59.28 and a day low of 58.44 with a total volume of 14,473,123. MRK had a previous close of 58.30 and has been seeing an average volume of 8,131,930.
Overall Average: 88% Buy
Recent stock forum discussions about MRK http://investorshangout.com/search?q=MRK&...mp;yt0=Go!
Achillion
at Investor's Business Daily - Fri Jun 20, 5:38PM CDT
Achillion (ACHN) shares rose 0.6% to 8.13 after R. W. Baird noted that Merck's (MRK) official tender offer indicated that there was another bidder for Idenix Pharmaceuticals, which means that a company is still looking for a nucleoside hepatitis C... (full story)
Is Gilead Sciences, Inc. Destined for Greatness?
Alex Planes, The Motley Fool - Motley Fool - Fri Jun 20, 5:00PM CDT
Investors love stocks that consistently beat the Street without getting ahead of their fundamentals and risking a meltdown. The best stocks offer sustainable market-beating gains, with robust and improving financial metrics that support strong price... (full story)
Tetraphase Progresses with Eravacycline Late-Stage Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jun 20, 4:20PM CDT
Tetraphase Pharmaceuticals (TTPH) announced the completion of patient enrolment for the phase III IGNITE 2 study on eravacycline. (full story)
Look for Shares of Merck to Potentially Pullback after Yesterday's 1.06% Rise
Comtex SmarTrend(R) - Fri Jun 20, 3:43PM CDT
Merck (NYSE:MRK) traded in a range yesterday that spanned from a low of $58.44 to a high of $59.28. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of $58.45 on volume of 14.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious. (full story)
After Yesterday's Rally of 1.06% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Fri Jun 20, 3:43PM CDT
Merck (NYSE:MRK) traded in a range yesterday that spanned from a low of $58.44 to a high of $59.28. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of $58.45 on volume of 14.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious. (full story)
Dow, S&P 500 End At New Highs, Led By Auto Retailers
at Investor's Business Daily - Fri Jun 20, 3:13PM CDT
Stocks rose Friday, with the Dow Jones industrial average and the S&P 500 ending at fresh record highs. The Dow Jones industrial average rose 0.2%. The broader Nasdaq and the S&P 500 edged up 0.1% each. Amid quadruple witching, volume was higher... (full story)
Why Caterpillar and Merck Are Climbing Today
Jay Jenkins, The Motley Fool - Motley Fool - Fri Jun 20, 12:04PM CDT
The Dow Jones Industrial Average is slightly higher so far in today's session, gaining 38 points as of 1:40 p.m. EDT. Two Dow components leading the index today are Caterpillar and Merck . Caterpillar: A strong ship sailing in high seas ... (full story)
Achillion Could Win Idenix's Mystery Suitor: Analyst
at Investor's Business Daily - Fri Jun 20, 11:44AM CDT
Hot biotech stock Achillion Pharmaceuticals (ACHN) was up 2%, near 8.20, in midday trading in the stock market today after an analyst found more support for its prospects as a buyout candidate. R. W. Baird's Brian Skorney noted that Merck's (MRK)... (full story)
Dow, S&P 500 Hit All-Time Highs As Volume Swells
at Investor's Business Daily - Fri Jun 20, 10:58AM CDT
With big-cap names leading the way, stocks were higher as the noon hour approached Friday with the Dow Jones industrial average and the S&P 500 hitting all-time highs. Volume swelled because of quadruple witching, the simultaneous quarterly... (full story)
Dow Today: Merck (MRK) Leads The Day Higher, International Business Machines (IBM) Lags
at The Street - Fri Jun 20, 9:00AM CDT
The Dow component leading the way higher looks to be Merck (NYSE: MRK ), which is sporting a 47-cent gain (+0.8%) bringing the stock to $58.77. Holding back the Dow today is International Business Machines (NYSE: IBM ), which is lagging the... (full story)
Merck (MRK) Highlighted As Momo Momentum Stock
at The Street - Fri Jun 20, 8:49AM CDT
Trade-Ideas LLC identified Merck (MRK) as a momo momentum candidate (full story)
Merck Begins Tender Offer to Acquire Idenix
Business Wire - Fri Jun 20, 6:30AM CDT
Merck (NYSE:MRK), known as MSD outside the United States and Canada, is commencing today, through a subsidiary, a cash tender offer to purchase all outstanding shares of common stock of Idenix Pharmaceuticals, Inc. (NASDAQ:IDIX). On June 09, 2014, Merck announced its intent to acquire Idenix. (full story)
Conference Call Schedules, Acquisitions, and Public Offerings - Analyst Notes on Johnson & Johnson, Merck, GW, Endocyte and AVEO
PR Newswire - Fri Jun 20, 5:10AM CDT
Today, Analysts Review released its analysts' notes regarding Johnson & Johnson (NYSE: JNJ), Merck & Co. Inc. (NYSE: MRK), GW Pharmaceuticals plc (NASDAQ: GWPH), Endocyte, Inc. (NASDAQ: ECYT) and AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3944-100free. (full story)
Alchemia Announces First Patient Enrolled in Investigator-Led Phase II Trial of HA-Irinotecan and Erbitux ("CHIME" Trial)
Marketwire - Fri Jun 20, 4:30AM CDT
Alchemia Limited (ASX: ACL), a drug discovery and development company, today announced that the first patient has been enrolled into the new clinical trial of HA-Irinotecan and Erbitux(R) (cetuximab); the CHIME trial. This clinical trial is being conducted as an Investigator-Sponsored trial and is jointly supported by Alchemia and Merck Serono SA (Merck Serono). The trial is being led by principal investigator, Associate Professor Peter Gibbs (Walter and Eliza Hall, Royal Melbourne Hospital and Western Hospital, Australia). (full story)
ABLYNX WINS TRANSACTION OF THE YEAR AT THE 2014 EUROPEAN MEDISCIENCE AWARDS
GlobeNewswire - Fri Jun 20, 12:05AM CDT
Ablynx [Euronext Brussels: ABLX] today announced that at the European Mediscience Awards 2014, the Company won the Transaction of the Year Award for its deal with AbbVie, worth up to US$840 million, for the development and commercialisation of its anti-IL-6R Nanobody(R) (ALX-0061) to treat inflammatory diseases. (full story)
Bigger, Faster, Stronger: 3 Great But Flawed Dow Dividends
Anders Bylund, The Motley Fool - Motley Fool - Thu Jun 19, 1:06PM CDT
The 30 Dow Jones Industrial Average stocks have everything an income investor might want. The blue-chip index includes a few components with high dividend yields, some with a proven history of growing their payouts like bamboo sprouts, and others... (full story)
Global Human Papillomavirus Infections Pipeline Analysis 2014
M2 - Thu Jun 19, 9:36AM CDT
Research and Markets (http://www.researchandmarkets.com/research/r42gfc/human) has announced the addition of the "Human Papillomavirus Infections Pipeline Analysis" report to their offering. Currently there is significant amount of research being undertaken to study the process of HPV infection causing precancerous changes in normal cells. Also, methods to prevent and manage this situation are also being analyzed. A majority of these studies were previously focusing on cervical cells in women. But in recent years, the realm of research has been extended to other tissues also in which HPV may cause cancer, such as the oropharynx and anus. Also, many organizations are analyzing the use of second-generation preventive vaccines along with therapeutic HPV vaccines, which could possibly prevent the development of cancer among women previously infected with HPV. Such an ideal vaccine strategy would combine a preventive and therapeutic vaccine, which would help in a major way. The mechanism of the HPV vaccines is similar to the other immunizations which help in protecting against viral infections. It has been observed and analyzed that the unique surface components of HPV have the capability to create an antibody response which could possibly protect the human body against infection. These components could thus be used as a basis of the vaccine. There are only 2 HPV vaccines which are currently marketed across the globe. Both these vaccines are prepared using the recombinant technology, which is taken from purified L1 structural proteins which self assemble to form HPV type-specific empty shells or virus-like particles (VLPs). Since there are no therapeutic HPV vaccines available at present which have proved their efficiency in the clinical trials, there is still a lot of work which is required in this field, thus opening a large window of opportunities. There have been some technological advancements in the past 4-5 years. The future is also likely to continue to witness similar technological and medical success in terms of new drugs and efficient vaccines, with the help of adequate funding. Certain developments like a new treatment to reduce transmissibility in drug users and new efforts to strengthen the immune system have the potential to develop further and provide better healthcare services to the patients in the future. Thus, there needs to be more focus being given to increasing the knowledge and awareness about HPV infections and the ways and methods to treat it, either through drugs or through vaccines. Human Papillomavirus Infections Vaccine Pipeline Analysis - Report Highlights: - Human Papillomavirus Vaccine Market Overview - Marketed Drug Profiles & Patent Analysis - Clinical Trial Insight by Phase & Country - Drug Clinical Development Phase: 47 - Suspended & Discontinued Drug Profiles: 46 - Competitive Landscape Companies Mentioned - Advanced Viral Research - BioSphings, - Biogen Idec, - EyeGene, - Helix BioPharma, - Inviragen, - MedImmune, - Merck & Co, - Valeant Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/r42gfc/human (full story)
Cervical Cancer Drug Market & Pipeline Insight Report 2014
M2 - Thu Jun 19, 7:37AM CDT
Research and Markets (http://www.researchandmarkets.com/research/q4nl8w/cervical_cancer) has announced the addition of the "Cervical Cancer Drug Market & Pipeline Insight" report to their offering. Cervical cancer is the third and fourth most common cause of cancer incidence and mortality among women across the world. Though there has been a decline in cervical cancer mortality rates in the previous few years, owing to early detection and intervention, challenges like over-diagnosis and over-treatment of the disease continue to remain. As per the World Health Organization (WHO), more than half a million new cases are diagnosed annually and there are close to 275,000 deaths every year. Thus, cervical cancer continues to be a major public health problem among the other cancers. Significant amount of research is being undertaken to study the process of HPV infection causing precancerous changes in normal cells, which eventually leads to cervical cancer. Also, methods to prevent and manage this situation are also being analyzed. A majority of these studies were previously focusing on cervical cells in women. But in recent years, the realm of research has been extended to other tissues also in which HPV may cause cancer, such as the oropharynx and anus. Once the results of these research activities are proved, there would be a major shift in the methods of treating this disease in the future. Since there are no therapeutic vaccines available at present which have proved their efficiency in the clinical trials, there is still a lot of work which is required in this field, thus opening a large window of opportunities. The current therapeutic vaccines have shown some systematic cellular immunity by intramuscular or subcutaneous injection. This has led the clinical trials to show cellular immune response to the vaccines. However, mucosal immunity at cervical mucosa is required and the pharma companies are currently focusing on this aspect. With the development of vaccines addressing this issue, there would be a significant reduction in the incidence rates of HPV across the globe. Efforts are being made by the stakeholders to invest larger quantities of time and resources in obtaining a greater and deeper understanding of laboratory research which has indicated that HPVs (which are the major cause of cervical cancer), produce proteins which are called E5, E6, and E7. These proteins tend to interfere with the functions of the cells which normally prevent excessive growth. With a better knowledge of the mechanisms and working of these proteins, researchers could possibly be able to develop successful ways to limit the process by which HPV infection can lead to the growth of abnormal cells, thus controlling the incidence of cervical cancer. Key Topics Covered: 1. Cervical Cancer Drug Market Overview - Market Overview - Clinical Pipeline Insight 2. Cervical Cancer Drug Clinical Trial Insight by Phase & Country - Preclinical - Clinical - Phase I - Phase I/II - Phase II - Phase III 3. Marketed Cervical Cancer Drug Clinical Insight & Patent Analysis 4. Discontinued & No Development Reported in Cervical Cancer Drug - No Development Reported - Discontinued 5. Competitive Landscape - Advaxis - ApoVax - Genentech - GlaxoSmithKline - ISA Pharmaceutical - Inovio Pharmaceuticals - Kaken Pharmaceutical - Merck For more information visit http://www.researchandmarkets.com/research/q4...cal_cancer (full story)
Down 14%: Is Endocyte a Bad News Buy?
Michael Douglass and David Williamson, The Motley Fool - Motley Fool - Wed Jun 18, 5:02PM CDT
Endocyte shares got hammered today on the disappointing news that partner Merck decided to hand back rights to vintafolide and leave the company to go it alone. Endocyte is waiting for more data from a phase 2b trial in non-small cell lung... (full story)
Overall Average: 88% Buy
Recent stock forum discussions about MRK http://investorshangout.com/search?q=MRK&...mp;yt0=Go!
Achillion
at Investor's Business Daily - Fri Jun 20, 5:38PM CDT
Achillion (ACHN) shares rose 0.6% to 8.13 after R. W. Baird noted that Merck's (MRK) official tender offer indicated that there was another bidder for Idenix Pharmaceuticals, which means that a company is still looking for a nucleoside hepatitis C... (full story)
Is Gilead Sciences, Inc. Destined for Greatness?
Alex Planes, The Motley Fool - Motley Fool - Fri Jun 20, 5:00PM CDT
Investors love stocks that consistently beat the Street without getting ahead of their fundamentals and risking a meltdown. The best stocks offer sustainable market-beating gains, with robust and improving financial metrics that support strong price... (full story)
Tetraphase Progresses with Eravacycline Late-Stage Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jun 20, 4:20PM CDT
Tetraphase Pharmaceuticals (TTPH) announced the completion of patient enrolment for the phase III IGNITE 2 study on eravacycline. (full story)
Look for Shares of Merck to Potentially Pullback after Yesterday's 1.06% Rise
Comtex SmarTrend(R) - Fri Jun 20, 3:43PM CDT
Merck (NYSE:MRK) traded in a range yesterday that spanned from a low of $58.44 to a high of $59.28. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of $58.45 on volume of 14.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious. (full story)
After Yesterday's Rally of 1.06% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Fri Jun 20, 3:43PM CDT
Merck (NYSE:MRK) traded in a range yesterday that spanned from a low of $58.44 to a high of $59.28. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of $58.45 on volume of 14.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious. (full story)
Dow, S&P 500 End At New Highs, Led By Auto Retailers
at Investor's Business Daily - Fri Jun 20, 3:13PM CDT
Stocks rose Friday, with the Dow Jones industrial average and the S&P 500 ending at fresh record highs. The Dow Jones industrial average rose 0.2%. The broader Nasdaq and the S&P 500 edged up 0.1% each. Amid quadruple witching, volume was higher... (full story)
Why Caterpillar and Merck Are Climbing Today
Jay Jenkins, The Motley Fool - Motley Fool - Fri Jun 20, 12:04PM CDT
The Dow Jones Industrial Average is slightly higher so far in today's session, gaining 38 points as of 1:40 p.m. EDT. Two Dow components leading the index today are Caterpillar and Merck . Caterpillar: A strong ship sailing in high seas ... (full story)
Achillion Could Win Idenix's Mystery Suitor: Analyst
at Investor's Business Daily - Fri Jun 20, 11:44AM CDT
Hot biotech stock Achillion Pharmaceuticals (ACHN) was up 2%, near 8.20, in midday trading in the stock market today after an analyst found more support for its prospects as a buyout candidate. R. W. Baird's Brian Skorney noted that Merck's (MRK)... (full story)
Dow, S&P 500 Hit All-Time Highs As Volume Swells
at Investor's Business Daily - Fri Jun 20, 10:58AM CDT
With big-cap names leading the way, stocks were higher as the noon hour approached Friday with the Dow Jones industrial average and the S&P 500 hitting all-time highs. Volume swelled because of quadruple witching, the simultaneous quarterly... (full story)
Dow Today: Merck (MRK) Leads The Day Higher, International Business Machines (IBM) Lags
at The Street - Fri Jun 20, 9:00AM CDT
The Dow component leading the way higher looks to be Merck (NYSE: MRK ), which is sporting a 47-cent gain (+0.8%) bringing the stock to $58.77. Holding back the Dow today is International Business Machines (NYSE: IBM ), which is lagging the... (full story)
Merck (MRK) Highlighted As Momo Momentum Stock
at The Street - Fri Jun 20, 8:49AM CDT
Trade-Ideas LLC identified Merck (MRK) as a momo momentum candidate (full story)
Merck Begins Tender Offer to Acquire Idenix
Business Wire - Fri Jun 20, 6:30AM CDT
Merck (NYSE:MRK), known as MSD outside the United States and Canada, is commencing today, through a subsidiary, a cash tender offer to purchase all outstanding shares of common stock of Idenix Pharmaceuticals, Inc. (NASDAQ:IDIX). On June 09, 2014, Merck announced its intent to acquire Idenix. (full story)
Conference Call Schedules, Acquisitions, and Public Offerings - Analyst Notes on Johnson & Johnson, Merck, GW, Endocyte and AVEO
PR Newswire - Fri Jun 20, 5:10AM CDT
Today, Analysts Review released its analysts' notes regarding Johnson & Johnson (NYSE: JNJ), Merck & Co. Inc. (NYSE: MRK), GW Pharmaceuticals plc (NASDAQ: GWPH), Endocyte, Inc. (NASDAQ: ECYT) and AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3944-100free. (full story)
Alchemia Announces First Patient Enrolled in Investigator-Led Phase II Trial of HA-Irinotecan and Erbitux ("CHIME" Trial)
Marketwire - Fri Jun 20, 4:30AM CDT
Alchemia Limited (ASX: ACL), a drug discovery and development company, today announced that the first patient has been enrolled into the new clinical trial of HA-Irinotecan and Erbitux(R) (cetuximab); the CHIME trial. This clinical trial is being conducted as an Investigator-Sponsored trial and is jointly supported by Alchemia and Merck Serono SA (Merck Serono). The trial is being led by principal investigator, Associate Professor Peter Gibbs (Walter and Eliza Hall, Royal Melbourne Hospital and Western Hospital, Australia). (full story)
ABLYNX WINS TRANSACTION OF THE YEAR AT THE 2014 EUROPEAN MEDISCIENCE AWARDS
GlobeNewswire - Fri Jun 20, 12:05AM CDT
Ablynx [Euronext Brussels: ABLX] today announced that at the European Mediscience Awards 2014, the Company won the Transaction of the Year Award for its deal with AbbVie, worth up to US$840 million, for the development and commercialisation of its anti-IL-6R Nanobody(R) (ALX-0061) to treat inflammatory diseases. (full story)
Bigger, Faster, Stronger: 3 Great But Flawed Dow Dividends
Anders Bylund, The Motley Fool - Motley Fool - Thu Jun 19, 1:06PM CDT
The 30 Dow Jones Industrial Average stocks have everything an income investor might want. The blue-chip index includes a few components with high dividend yields, some with a proven history of growing their payouts like bamboo sprouts, and others... (full story)
Global Human Papillomavirus Infections Pipeline Analysis 2014
M2 - Thu Jun 19, 9:36AM CDT
Research and Markets (http://www.researchandmarkets.com/research/r42gfc/human) has announced the addition of the "Human Papillomavirus Infections Pipeline Analysis" report to their offering. Currently there is significant amount of research being undertaken to study the process of HPV infection causing precancerous changes in normal cells. Also, methods to prevent and manage this situation are also being analyzed. A majority of these studies were previously focusing on cervical cells in women. But in recent years, the realm of research has been extended to other tissues also in which HPV may cause cancer, such as the oropharynx and anus. Also, many organizations are analyzing the use of second-generation preventive vaccines along with therapeutic HPV vaccines, which could possibly prevent the development of cancer among women previously infected with HPV. Such an ideal vaccine strategy would combine a preventive and therapeutic vaccine, which would help in a major way. The mechanism of the HPV vaccines is similar to the other immunizations which help in protecting against viral infections. It has been observed and analyzed that the unique surface components of HPV have the capability to create an antibody response which could possibly protect the human body against infection. These components could thus be used as a basis of the vaccine. There are only 2 HPV vaccines which are currently marketed across the globe. Both these vaccines are prepared using the recombinant technology, which is taken from purified L1 structural proteins which self assemble to form HPV type-specific empty shells or virus-like particles (VLPs). Since there are no therapeutic HPV vaccines available at present which have proved their efficiency in the clinical trials, there is still a lot of work which is required in this field, thus opening a large window of opportunities. There have been some technological advancements in the past 4-5 years. The future is also likely to continue to witness similar technological and medical success in terms of new drugs and efficient vaccines, with the help of adequate funding. Certain developments like a new treatment to reduce transmissibility in drug users and new efforts to strengthen the immune system have the potential to develop further and provide better healthcare services to the patients in the future. Thus, there needs to be more focus being given to increasing the knowledge and awareness about HPV infections and the ways and methods to treat it, either through drugs or through vaccines. Human Papillomavirus Infections Vaccine Pipeline Analysis - Report Highlights: - Human Papillomavirus Vaccine Market Overview - Marketed Drug Profiles & Patent Analysis - Clinical Trial Insight by Phase & Country - Drug Clinical Development Phase: 47 - Suspended & Discontinued Drug Profiles: 46 - Competitive Landscape Companies Mentioned - Advanced Viral Research - BioSphings, - Biogen Idec, - EyeGene, - Helix BioPharma, - Inviragen, - MedImmune, - Merck & Co, - Valeant Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/r42gfc/human (full story)
Cervical Cancer Drug Market & Pipeline Insight Report 2014
M2 - Thu Jun 19, 7:37AM CDT
Research and Markets (http://www.researchandmarkets.com/research/q4nl8w/cervical_cancer) has announced the addition of the "Cervical Cancer Drug Market & Pipeline Insight" report to their offering. Cervical cancer is the third and fourth most common cause of cancer incidence and mortality among women across the world. Though there has been a decline in cervical cancer mortality rates in the previous few years, owing to early detection and intervention, challenges like over-diagnosis and over-treatment of the disease continue to remain. As per the World Health Organization (WHO), more than half a million new cases are diagnosed annually and there are close to 275,000 deaths every year. Thus, cervical cancer continues to be a major public health problem among the other cancers. Significant amount of research is being undertaken to study the process of HPV infection causing precancerous changes in normal cells, which eventually leads to cervical cancer. Also, methods to prevent and manage this situation are also being analyzed. A majority of these studies were previously focusing on cervical cells in women. But in recent years, the realm of research has been extended to other tissues also in which HPV may cause cancer, such as the oropharynx and anus. Once the results of these research activities are proved, there would be a major shift in the methods of treating this disease in the future. Since there are no therapeutic vaccines available at present which have proved their efficiency in the clinical trials, there is still a lot of work which is required in this field, thus opening a large window of opportunities. The current therapeutic vaccines have shown some systematic cellular immunity by intramuscular or subcutaneous injection. This has led the clinical trials to show cellular immune response to the vaccines. However, mucosal immunity at cervical mucosa is required and the pharma companies are currently focusing on this aspect. With the development of vaccines addressing this issue, there would be a significant reduction in the incidence rates of HPV across the globe. Efforts are being made by the stakeholders to invest larger quantities of time and resources in obtaining a greater and deeper understanding of laboratory research which has indicated that HPVs (which are the major cause of cervical cancer), produce proteins which are called E5, E6, and E7. These proteins tend to interfere with the functions of the cells which normally prevent excessive growth. With a better knowledge of the mechanisms and working of these proteins, researchers could possibly be able to develop successful ways to limit the process by which HPV infection can lead to the growth of abnormal cells, thus controlling the incidence of cervical cancer. Key Topics Covered: 1. Cervical Cancer Drug Market Overview - Market Overview - Clinical Pipeline Insight 2. Cervical Cancer Drug Clinical Trial Insight by Phase & Country - Preclinical - Clinical - Phase I - Phase I/II - Phase II - Phase III 3. Marketed Cervical Cancer Drug Clinical Insight & Patent Analysis 4. Discontinued & No Development Reported in Cervical Cancer Drug - No Development Reported - Discontinued 5. Competitive Landscape - Advaxis - ApoVax - Genentech - GlaxoSmithKline - ISA Pharmaceutical - Inovio Pharmaceuticals - Kaken Pharmaceutical - Merck For more information visit http://www.researchandmarkets.com/research/q4...cal_cancer (full story)
Down 14%: Is Endocyte a Bad News Buy?
Michael Douglass and David Williamson, The Motley Fool - Motley Fool - Wed Jun 18, 5:02PM CDT
Endocyte shares got hammered today on the disappointing news that partner Merck decided to hand back rights to vintafolide and leave the company to go it alone. Endocyte is waiting for more data from a phase 2b trial in non-small cell lung... (full story)
